E

Targeting Natural Killer Cells in Cancer Immunotherapy

Can we address inhibitory factors that dampen NK cells to enhance the anti-cancer effect on tumours?

October 11, 2017
E

Immunotherapy Possibilities in Pancreatic Cancer

A look at what's different about exceptional responders in PDAC and what can we learn about neoantigen approaches here?

October 5, 2017
E

The Future of Cancer Vaccines Part 5 – An Interview with Prof George Coukos

A look at the latest developments in cancer immunotherapy in ovarian cancer, with a particular focus on neoepitopes and cancer vaccines.

October 3, 2017
E

The Future of Cancer Vaccines Part 4 – An Interview with Prof Kees Melief

Interview with Prof Kees Melief, CSO ISA Immune System Activation Pharmaceuticals

October 2, 2017
E

The Future of Cancer Vaccines Part 3 – Interview with Prof Ugur Sahin

A look at Ugur Sahin's BioNTech and personalized mRNA vaccines

September 28, 2017
E

The Future of Cancer Vaccines Part 2 – interview with Dr Ira Mellman

Genentech have several cancer vaccine collaborations in place, where do they see the future going in this niche?

September 27, 2017
E

The Future of Cancer Vaccines – An Interview with Dr Cathy Wu

Part 1 of a new mini-series on cancer vaccines. This one covers an update on Neon's neoantigen approach...

September 26, 2017
E

How to disrupt the CAR T cell therapy space

Is the CAR T cell therapy space ready for disruption? At least one researcher thinks so. What does this entail?

September 21, 2017
E

Can this novel combination overcome resistance to checkpoint blockade?

An early look at a new IO combination that may help overcome resistance to checkpoint therapy

September 14, 2017
E

Corvus moves fast to target tumor microenvironment and improve checkpoint responses

Corvus Pharmaceuticals accelerates development of A2A receptor antagonist CPI-444 that could improve checkpoint responses.

September 26, 2016